| 07:55–08:55 Cubex A1 + A2 |
Breakfast & INDUSTRY SYMPOSIUM |
| 09:00–10:00 Cubex A1 + A2 |
Perspectives in IgAN: Where are we and where do we need to go next? Chairs: Loreto Gesualdo, Ali Gharavi Speakers: Terry Cook, John Feehally, Vlado Perkovic |
| 10:00–11:00 Cubex A1 + A2 |
PLENARY SESSION 7: IgAN & IgAV in children Chairs: Evangeline Pillebout, Richard Lafayette Alexandra Cambier: Are there fundamental differences between IgAN/IgAV in adults and children? Louise Oni: How do we advance treatment for children with IgAN & IgAV? Marina Vivarelli: Beyond the IPNA Guidelines-Treatment of IgAN & IgAV |
| 11:00–11:30 |
Coffee break |
| 11:30–11:50 Cubex A1 + A2 |
PLENARY SESSION 8: IIGANN Research Group Lecture 3 Chair: Ian Roberts Julio Saez-Rodriguez: The IgAN Atlas |
| 11:50–13:00 Cubex A1 + A2 |
FREE COMMUNICATIONS Jenna Keung: Investigating patient heterogeneity using deconvolution and multicellular factor analysis in IgA nephropathy Turgay Saritas: Single-Cell Multiomic Profiling of PBMCs Reveals Immune Heterogeneity and Therapeutic Target Expression in IgA Nephropathy Qiaoping Chen: Single-cell transcriptomics and urine proteomics reveals immune dysregulation and macrophage lipid accumulation in HSPN Miguel A. Hernandez-Hernandez: Single cell spatial transcriptomics of human kidney biopsies reveals structural and molecular features of crescent formation in IgA nephropathy Xiaohong Zheng: Exploring immune mechanisms in pediatric IgA nephropathy through spatial transcriptomics Alexandra Cambier: Deciphering APRIL’s involvement in the pathogenesis of childhood IgA nephropathy Srishti Sahu: Deciphering complement pathway activation mechanisms in childhood IgA nephropathy |
| 13:00–14:00 Cubex A1 + A2 |
Lunch & INDUSTRY SYMPOSIUM |
| 14:00–15:00 Cubex A1 + A2 |
PLENARY SESSION 9: Treatment 2 Chairs: Brad Rovin, Muh Geot Wong Jicheng Lv: Targeting IgA immune complex driven inflammation and fibrosis Yusuke Suzuki: Targeting production of pathogenic IgA Jonathan Barratt: How will the KDIGO Guidelines evolve over the next 5 years? |
| 15:00–15:30 Cubex A1 + A2 |
FREE COMMUNICATIONS Arvind Madan: Longer follow-up of povetacicept shows potential for treatment of IgA nephropathy (RUBY-3 study) Michael Wang: FB-7011: A Novel, Long-Duration siRNA Dual-Targeting Both Complement Factor B (CFB) and Mannan-Binding Lectin Serine Protease 2 (MASP2) Exhibits Therapeutic Potential for Treatment of IgA Nephropathy Xiaohong Zheng: Tolerogenic dendritic cells immunotherapy protects against IgA nephropathy |
| 15:30–16:00 |
Coffee break |
| 16:00–17:00 Cubex A1 + A2 |
CONCLUDING REMARKS & PRIZE PRESENTATION |
Last update on 15 July 2025.
The programme might be subject to necessary changes.
